Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients
Status:
Completed
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Patients with histologically or cytologically confirmed stage IIIB or IV ALK-negative
non-small-cell lung cancer (NSCLC) participated in this study following the failure of
initial treatments. The ALK phosphorylation expression was detected in histologic samples of
patients. patients with positive ALK phosphorylation expression were treated with crizotinib
.